Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project.

BACKGROUND Recent reports have suggested that anemia is associated with adverse outcomes in patients with heart failure (HF), but were unable to adjust for a broad range of comorbid conditions. As a result, whether anemia is a truly independent predictor of risk or a marker of comorbid illness in these patients is unknown. METHODS We analyzed medical records from the Centers for Medicare & Medicaid Services' National Heart Care Project, a national sample of 50,405 patients 65 years and older admitted to acute care hospitals with a principal discharge diagnosis of HF between April 1, 1998, and March 31, 1999, or between July 1, 2000, and June 30, 2001. Multivariable logistic regression analyses were conducted to test whether hematocrit level was an independent predictor of all-cause mortality and HF-related readmission at 1 year. RESULTS In unadjusted analysis, lower hematocrit levels were associated with increased 1-year mortality and readmission for HF. Compared with patients with a hematocrit greater than 40% to 44%, those with a hematocrit of 24% or less had a 51% higher risk of death (relative risk [RR], 1.51; 95% confidence interval [CI], 1.35-1.68; P<.001) and a 17% higher risk of HF-related readmission (RR, 1.17; 95% CI, 1.01-1.34; P = .04). However, after adjustment for multiple comorbidities and other clinical factors, the association between lower hematocrit levels and increased 1-year mortality was markedly attenuated, even in those patients with the most severe anemia (hematocrit, < or = 24% vs > 40%-44%: RR, 1.02; 95% CI, 0.86-1.19; P = .85). The association between lower hematocrit values and HF-related readmission persisted after multivariable adjustment (hematocrit, < or = 24% vs > 40%-44%: RR, 1.21; 95% CI, 1.04-1.38; P = .01). CONCLUSIONS Although anemia is an independent predictor of hospital readmission, its relationship with increased mortality in HF patients is largely explained by the severity of comorbid illness. These findings suggest that anemia may be predominantly a marker rather than a mediator of increased mortality risk in older patients with HF.

[1]  P. Poole‐Wilson,et al.  Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. , 2004, European heart journal.

[2]  J. McMurray,et al.  Anemia and Its Relationship to Clinical Outcome in Heart Failure , 2004, Circulation.

[3]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[4]  M. Mitka.  Researchers probe anemia-heart failure link. , 2003, JAMA.

[5]  J. Ryu,et al.  Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin , 2003 .

[6]  Albert W Wu,et al.  Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[7]  C. O'connor,et al.  Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. , 2003, The American journal of cardiology.

[8]  P. Poole‐Wilson,et al.  Haemoglobin concentration and prognosis in new cases of heart failure , 2003, The Lancet.

[9]  D. Mozaffarian,et al.  Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). , 2003, Journal of the American College of Cardiology.

[10]  Harlan M Krumholz,et al.  The prognostic importance of anemia in patients with heart failure. , 2003, The American journal of medicine.

[11]  C. Lang,et al.  Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.

[12]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[13]  L. Lund,et al.  Hemodilution Is Common in Patients With Advanced Heart Failure , 2003, Circulation.

[14]  J. Ryu,et al.  Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin , 2003, Cancer.

[15]  D. Silverberg,et al.  The importance of anemia and its correction in the management of severe congestive heart failure , 2002, European journal of heart failure.

[16]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[17]  C. Jurkovitz,et al.  Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. , 2002, Journal of the American Society of Nephrology : JASN.

[18]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[19]  H. Krumholz,et al.  Spectrum of heart failure in older patients: results from the National Heart Failure project. , 2002, American heart journal.

[20]  W. Hörl,et al.  Effect of erythropoietin on cardiovascular diseases. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[22]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[23]  F. Valderrábano,et al.  Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. , 2000, Journal of the American Society of Nephrology : JASN.

[24]  M. Nichaman,et al.  Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. , 2000, Archives of internal medicine.

[25]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[26]  Y Wang,et al.  Predictors of readmission among elderly survivors of admission with heart failure. , 2000, American heart journal.

[27]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[28]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[29]  E. Fisher,et al.  Hospital readmission rates for cohorts of Medicare beneficiaries in Boston and New Haven. , 1994, The New England journal of medicine.

[30]  P. Poole‐Wilson,et al.  Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. , 1993, British heart journal.

[31]  J. Concato,et al.  Problems of comorbidity in mortality after prostatectomy. , 1992, JAMA.

[32]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[33]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .